Archive
All News
Every briefing, headline, and filing we've published, newest first.
DealsFierceBiotech ↗
UCB has struck a deal to acquire Candid Therapeutics for $2 billion upfront, hijacking a planned reverse merge…
MoneyFiercePharma ↗
Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star hear…
PolicyBriefing
The final rule adds disclosure requirements for SSBCI benefits but eases prior consumer protection measures ar…
DataDrug Channels ↗
By Adam J. Fein, Ph.D.The Drug Channels Institute (DCI) team attended Asembia’s AXS26 Summit last week. Once a…
PolicySTAT News ↗
Supreme Court restores access to abortion pill mifepristone through telehealth, mail, and pharmacies
The Supreme Court on Monday restored broad access to the abortion pill mifepristone, blocking a ruling that ha…
MoneyBioPharma Dive ↗
The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enab…
PipelinePharmaVoice ↗
Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrow…
PipelineFiercePharma ↗
The early FDA approval doesn't change Pfizer and Arvinas' plan to leave commercialization of the drug to a yet…
PipelineFierceBiotech ↗
Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing programs it once predicted could deliv…
PipelineBriefing
Auvelity, already cleared for depression, becomes the first non-antipsychotic treatment for agitation in Alzhe…
DealsEndpoints News ↗
Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in auto…
PipelineFiercePharma ↗
A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ s…
PeopleFierceBiotech ↗
Katherine Szarama, Ph.D., will take over as CBER director in an acting capacity while the search for a permane…
MoneyBriefing
Seaport Therapeutics opted for a $255M Nasdaq IPO over an acquisition, underscoring renewed investor appetite …
PolicySTAT News ↗
Mifepristone, involved in most abortions in the U.S., can now be distributed only in person and at clinics.…
DealsFiercePharma ↗
Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema…
PipelineFierceBiotech ↗
An FDA expert panel on Thursday voted 6 to 3 against AstraZeneca's proposal of using its oral SERD camizestran…
PipelineBriefing
FDA authorizes Auvelity for agitation tied to Alzheimer’s disease, positioning Axsome’s NMDA/sigma-1 modulator…
PipelineBioPharma Dive ↗
Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still…
MoneyBioPharma Dive ↗
The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turna…
![<![CDATA[CAQH Index Finds $20 Billion in Cost Savings Opportunities]]>](https://images.builtfor.ai/images/article-images/cdata-caqh-index-finds-20-billion-in-cost-savings-opportunit.jpg)
MoneyEndpoints News ↗
A trio of biotechs priced their IPOs on Thursday into Friday morning, setting the stage for their public tradi…
MoneyFiercePharma ↗
As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugm…
DealsFierceBiotech ↗
Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million upfront, positioning the dru…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.